Payment overview · 2025
General Payments
$1,072.70
57 reported records · 19 companies
Healthcare provider profile · identity verified
Clayton Pickering, DO
Allopathic & Osteopathic Physicians|Family Medicine · WHITNEY, TX · NPI 1689667826
Verified facts
What the public records show
CMS Open Payments records show Clayton Pickering, DO received $1,072.70 in general payments during 2025 across 57 reported records.
Lundbeck LLC accounted for 23.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 27 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Farxiga, Kerendia, Linzess, Mounjaro, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 112 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 165 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 163 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 215 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lundbeck LLC | Unresolved — no canonical attribution shown | $249.85 | 23.3% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $165.10 | 15.4% | 15 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $128.08 | 11.9% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $63.20 | 5.9% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $50.34 | 4.7% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $49.96 | 4.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $49.36 | 4.6% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $38.25 | 3.6% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $35.53 | 3.3% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $35.42 | 3.3% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $34.42 | 3.2% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $33.94 | 3.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $26.50 | 2.5% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $24.06 | 2.2% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $22.46 | 2.1% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $21.73 | 2.0% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.58 | 1.6% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $14.55 | 1.4% | 1 | 2025 |
| Advanced Oxygen Therapy Inc. | Unresolved — no canonical attribution shown | $13.37 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,072.70 | 57 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $283.79 | 10 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $128.08 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $86.79 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $63.20 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $50.34 | 3 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $49.96 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $47.04 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $42.44 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $42.44 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $38.25 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $35.87 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $35.42 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $34.42 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $31.74 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $26.50 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $24.06 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $22.46 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $21.82 | 1 | 2025 |
Source payment records
|
|||||
| ZURZUVAE Normalized: zurzuvae |
Drug | Biogen, Inc. | $21.73 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $21.62 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $17.62 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $17.06 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $16.58 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.61 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $14.55 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.71 | 1 | 2025 |
Source payment records
|
|||||
| Topical Oxygen Chamber for extremities Normalized: topical oxygen chamber for extremities |
Device | Advanced Oxygen Therapy Inc. | $13.37 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 165 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 112 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 215 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 87 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 163 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
112 | 20 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
126 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
165 | 24 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
163 | 31 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
86 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
215 | 38 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
79 | 13 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
87 | 20 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
62 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 882 | 183 |
| Gabapentin | Gabapentin | 708 | 121 |
| Levothyroxine Sodium | Levothyroxine Sodium | 636 | 114 |
| Pantoprazole Sodium | Pantoprazole Sodium | 551 | 110 |
| Furosemide | Furosemide | 535 | 102 |
| Potassium Chloride | Potassium Chloride | 523 | 80 |
| Amlodipine Besylate | Amlodipine Besylate | 499 | 107 |
| Lisinopril | Lisinopril | 378 | 104 |
| Omeprazole | Omeprazole | 349 | 73 |
| Losartan Potassium | Losartan Potassium | 344 | 72 |
| Tramadol Hcl | Tramadol Hcl | 325 | 68 |
| Eliquis | Apixaban | 311 | 35 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 305 | 53 |
| Escitalopram Oxalate | Escitalopram Oxalate | 295 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 275 | 53 |
| Duloxetine Hcl | Duloxetine Hcl | 271 | 56 |
| Clopidogrel | Clopidogrel Bisulfate | 264 | 47 |
| Metoprolol Tartrate | Metoprolol Tartrate | 262 | 43 |
| Trazodone Hcl | Trazodone Hcl | 257 | 66 |
| Carvedilol | Carvedilol | 242 | 51 |
| Sertraline Hcl | Sertraline Hcl | 225 | 49 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 222 | 62 |
| Mounjaro | Tirzepatide | 215 | 38 |
| Memantine Hcl | Memantine Hcl | 209 | 23 |
| Metformin Hcl Er | Metformin Hcl | 199 | 44 |
| Mirtazapine | Mirtazapine | 194 | 43 |
| Metoprolol Succinate | Metoprolol Succinate | 186 | 50 |
| Metformin Hcl | Metformin Hcl | 172 | 40 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 170 | 44 |
| Montelukast Sodium | Montelukast Sodium | 169 | 35 |
| Tizanidine Hcl | Tizanidine Hcl | 168 | 37 |
| Farxiga | Dapagliflozin Propanediol | 165 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 163 | 31 |
| Donepezil Hcl | Donepezil Hcl | 153 | 21 |
| Lorazepam | Lorazepam | 151 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 142 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 141 | 39 |
| Meloxicam | Meloxicam | 139 | 31 |
| Baclofen | Baclofen | 135 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 133 | 23 |
| Januvia | Sitagliptin Phosphate | 127 | suppressed |
| Myrbetriq | Mirabegron | 126 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 116 | 32 |
| Linzess | Linaclotide | 112 | 20 |
| Glipizide | Glipizide | 109 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 107 | 32 |
| Methocarbamol | Methocarbamol | 107 | 25 |
| Allopurinol | Allopurinol | 103 | 21 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 103 | 34 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 100 | 25 |
| Celecoxib | Celecoxib | 99 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 94 | 17 |
| Pregabalin | Pregabalin | 90 | 19 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 89 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 88 | 17 |
| Ozempic | Semaglutide | 87 | 20 |
| Promethazine Hcl | Promethazine Hcl | 87 | suppressed |
| Jardiance | Empagliflozin | 86 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 86 | 17 |
| Lamotrigine | Lamotrigine | 85 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 83 | 17 |
| Buspirone Hcl | Buspirone Hcl | 82 | 25 |
| Latanoprost | Latanoprost | 81 | 11 |
| Torsemide | Torsemide | 80 | 13 |
| Trulicity | Dulaglutide | 79 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 77 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 77 | 41 |
| Oxybutynin Chloride | Oxybutynin Chloride | 75 | 13 |
| Alprazolam | Alprazolam | 74 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 74 | 21 |
| Eszopiclone | Eszopiclone | 73 | 21 |
| Levetiracetam | Levetiracetam | 71 | suppressed |
| Simvastatin | Simvastatin | 70 | 25 |
| Divalproex Sodium | Divalproex Sodium | 69 | suppressed |
| Famotidine | Famotidine | 68 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 68 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 68 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 67 | 18 |
| Dicyclomine Hcl | Dicyclomine Hcl | 67 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 67 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 67 | 21 |
| Spironolactone | Spironolactone | 67 | 17 |
| Temazepam | Temazepam | 67 | 13 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 66 | suppressed |
| Xarelto | Rivaroxaban | 66 | suppressed |
| Entresto | Sacubitril/Valsartan | 65 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 65 | 19 |
| Topiramate | Topiramate | 65 | 14 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 62 | suppressed |
| Clonazepam | Clonazepam | 57 | 12 |
| Nystatin | Nystatin | 56 | 29 |
| Glipizide Er | Glipizide | 55 | 13 |
| Metolazone | Metolazone | 54 | suppressed |
| Atenolol | Atenolol | 51 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 50 | 14 |
| Ezetimibe | Ezetimibe | 49 | suppressed |
| Naproxen | Naproxen | 48 | suppressed |
| Azithromycin | Azithromycin | 47 | 39 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 46 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 46 | 15 |
| Prednisone | Prednisone | 44 | 18 |
| Dapagliflozin | Dapagliflozin Propanediol | 43 | 11 |
| Ibuprofen | Ibuprofen | 43 | 15 |
| Methenamine Hippurate | Methenamine Hippurate | 43 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 42 | 29 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 42 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 41 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 40 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 40 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 40 | suppressed |
| Aripiprazole | Aripiprazole | 39 | suppressed |
| Finasteride | Finasteride | 39 | suppressed |
| Nifedipine Er | Nifedipine | 39 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 39 | 30 |
| Albuterol Sulfate | Albuterol Sulfate | 38 | 20 |
| Calcitriol | Calcitriol | 38 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | suppressed |
| Ondansetron Odt | Ondansetron | 38 | 22 |
| Alendronate Sodium | Alendronate Sodium | 37 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 37 | suppressed |
| Risperidone | Risperidone | 37 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 37 | 12 |
| Digoxin | Digoxin | 35 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 35 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 34 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 33 | suppressed |
| Bupropion Xl | Bupropion Hcl | 32 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 19 |
| Doxepin Hcl | Doxepin Hcl | 32 | suppressed |
| Cefdinir | Cefdinir | 31 | 23 |
| Cephalexin | Cephalexin | 31 | 21 |
| Methylprednisolone | Methylprednisolone | 31 | 30 |
| Prazosin Hcl | Prazosin Hcl | 31 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 30 | suppressed |
| Sucralfate | Sucralfate | 30 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 29 | suppressed |
| Novolog Flexpen | Insulin Aspart | 29 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 28 | 11 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 27 | suppressed |
| Budesonide | Budesonide | 27 | 26 |
| Testosterone Cypionate | Testosterone Cypionate | 27 | 14 |
| Creon | Lipase/Protease/Amylase | 26 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 26 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Pure Comfort Safety Pen Needle | Pen Needle, Diabetic, Safety | 26 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 26 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 25 | suppressed |
| Estradiol | Estradiol | 25 | suppressed |
| Lidocaine | Lidocaine | 25 | suppressed |
| Acyclovir | Acyclovir | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 24 | suppressed |
| Nitroglycerin | Nitroglycerin | 24 | 13 |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Timolol Maleate | Timolol Maleate | 24 | suppressed |
| Cilostazol | Cilostazol | 23 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | suppressed |
| Levemir | Insulin Detemir | 23 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 23 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 23 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 22 | suppressed |
| Belsomra | Suvorexant | 22 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 22 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 22 | suppressed |
| Repatha Sureclick | Evolocumab | 22 | suppressed |
| Rexulti | Brexpiprazole | 22 | suppressed |
| Anastrozole | Anastrozole | 21 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 21 | suppressed |
| Methadone Hcl | Methadone Hcl | 21 | suppressed |
| Olanzapine | Olanzapine | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 20 | 18 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 20 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 20 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Telmisartan | Telmisartan | 20 | suppressed |
| Lacosamide | Lacosamide | 19 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 18 | 13 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 18 | suppressed |
| Rybelsus | Semaglutide | 18 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 18 | suppressed |
| Fluconazole | Fluconazole | 17 | suppressed |
| Folic Acid | Folic Acid | 17 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 17 | suppressed |
| Acetazolamide | Acetazolamide | 16 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Mupirocin | Mupirocin | 16 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 16 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Carbamazepine Er | Carbamazepine | 14 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 14 | suppressed |
| Kerendia | Finerenone | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Levofloxacin | Levofloxacin | 14 | 14 |
| Nuplazid | Pimavanserin Tartrate | 14 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 14 | suppressed |
| Premarin | Estrogens, Conjugated | 14 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 13 | suppressed |
| Cholestyramine Light | Cholestyramine | 13 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Leucovorin Calcium | Leucovorin Calcium | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | suppressed |
| Modafinil | Modafinil | 13 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 13 | suppressed |
| Valproic Acid | Valproic Acid | 13 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 13 | suppressed |
| Ajovy Syringe | Fremanezumab-Vfrm | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Epinephrine | Epinephrine | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Leflunomide | Leflunomide | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,072.70 · 57 records | Lundbeck LLC | AIRSUPRA, AUSTEDO XR, Auvelity, CAPLYTA, CREON, Cologuard Collection Kit, EVENITY, FARXIGA, Kerendia, LINZESS, MOUNJARO, NUZYRA, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, Topical Oxygen Chamber for extremities, UBRELVY, VRAYLAR, Veozah, XIFAXAN, ZENPEP, ZEPBOUND, ZURZUVAE | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error